Vascular Function, Endothelin, and Inflammation in Pre-diabetic Obesity Versus Lean Healthy Controls

NCT ID: NCT00837590

Last Updated: 2019-08-01

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-03-31
• Study Completion Date: 2010-08-31

Brief Summary

Aims:

1. Does inflammation contribute importantly to concurrent defects in vascular and metabolic dysfunction in human pre-diabetic obesity?

2. Are there benefits of anti-inflammatory treatment strategies in pre-diabetic obesity in the context of existing treatment with metformin?

3. Are there benefits of anti-inflammatory treatment strategies in pre-diabetic obesity in the context of existing treatment with lisinopril?

Detailed Description

We set out to pursue the following Aims:

1. Does inflammation contribute importantly to concurrent defects in vascular and metabolic dysfunction in human pre-diabetic obesity? Pilot studies were performed exploring the acute actions of salsalate on vascular function, the chronic actions of salasate in obese individuals, and actions of chronic salsalate to prevent vascular dysfunction induced by fatty acids in lean individuals.

2. Are there benefits of anti-inflammatory treatment strategies in pre-diabetic obesity in the context of existing treatment with metformin? No studies were performed

3. Are there benefits of anti-inflammatory treatment strategies in pre-diabetic obesity in the context of existing treatment with lisinopril? No studies were performed

The intent of the current project is to efficiently and at low cost generate preliminary data along each of these lines of questioning, studying the minimum number of subjects required to assess the viability of the question using the current measurement approaches.

Conditions

Pre-diabetes; Obesity

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Acute Salsalate

Nondiabetic lean and obese subjects will be studied in this arm. Subjects will be studied at baseline and after a single dose of oral salsalate.

Group Type: EXPERIMENTAL

Acute Salsalate

Intervention Type: DRUG

Subjects will receive a single oral dose of 2 gram of oral salsalate

Chronic Salsalate - Obese

Obese subjects will be studied in this arm. Subjects will be studied at baseline and after 2 months' treatment with oral salsalate.

Group Type: EXPERIMENTAL

Chronic salsalate

Intervention Type: DRUG

Subjects will receive 2 months of treatment with 4 gram/day of oral salsalate divided into 3 doses.

Chronic Salsalate - Lean

Lean subjects will be studied in this arm. Subjects will be studied at baseline and after 2 months' treatment with oral salsalate. The effects of an acute fatty acid infusion on vascular function will be measured on both occasions.

Group Type: EXPERIMENTAL

Chronic salsalate

Intervention Type: DRUG

Subjects will receive 2 months of treatment with 4 gram/day of oral salsalate divided into 3 doses.

Interventions

Chronic salsalate

Subjects will receive 2 months of treatment with 4 gram/day of oral salsalate divided into 3 doses.

Intervention Type: DRUG

Acute Salsalate

Subjects will receive a single oral dose of 2 gram of oral salsalate

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• healthy
• normotensive (BP<140/95 mmHg)
• lean and obese
• 18 and 55 years
• women must be premenopausal

Exclusion Criteria

• use of pharmacologic agents or recreational drugs, with the exception of occasional use of non-narcotic pain medications
• blood pressure (>140/90 mmHg)
• elevated cholesterol (LDL >130 mg/dL)
• diabetes mellitus (by ADA criteria)
• evidence of coronary and/or peripheral vascular disease by history and physical exam
• >5 kg change in weight in the preceding 3 months
• chronic systemic illness with recognized metabolic effects
• hepatitis C and HIV
• recognized systemic inflammatory or autoimmune processes such as rheumatoid arthritis or systemic lupus erythematosis
• Raynaud's phenomenon or other abnormalities of hand or finger perfusion
• regular participation in endurance or high-performance athletic activity
• history of aspirin or salsalate sensitivity including aspirin-induced asthma
• prior treatment with salsalate, pentoxyfilline, or monoclonal anti-TNFalpha antibodies
• pregnancy
• liver transaminase levels >3 times the upper limit of normal
• creatinine >1.5 mg/dL
• history of a cellular immunodeficiency-related opportunistic infections, such as an endemic mycosis (eg. histoplasmosis) or mycobacterial infection (eg tuberculosis)
• reactive tuberculin skin test
• history of malignancy except for basal cell carcinoma of the skin

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Indiana University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kieren J Mather, MD

Role: PRINCIPAL_INVESTIGATOR

Indiana University

Locations

Indiana Clinical Research Center

Indianapolis, Indiana, United States

Countries

United States

Other Identifiers

IU-IRB-0901-03

Identifier Type: -

Identifier Source: org_study_id